同济大学学报（医学版）2018，Vol.39Issue(2)：1-6,6.DOI:10.16118/j.1008-0392.2018.02.001
银屑病生物制剂的发展与挑战
Research progress of biologic agents in psoriasis treatment
摘要
Abstract
Psoriasis is a common chronic inflammatory skin disease which cannot be cured currently. The treatment of moderate-to-severe plaque psoriasis has been revolutionized with the development of biologic agents for nearly 20 years. T cells and related cytokines, such as tumor necrosis factor-α(TNF-α), IL-23 and IL-17 play important roles in the pathogenesis of psoriasis. Several biologic agents targeting T cells,TNF-α,IL-23,IL-17 or their receptors show great efficacy in treatment of moderate-to-severe psoriasis.关键词
生物制剂/银屑病/白细胞介素23/白细胞介素17/肿瘤坏死因子αKey words
biologic agents/psoriasis/interleukin-23/interleukin-17/tumor necrosis factor-α分类
医药卫生引用本文复制引用
史玉玲..银屑病生物制剂的发展与挑战[J].同济大学学报（医学版）,2018,39(2):1-6,6.基金项目
国家自然科学基金(81673050,81301356) （81673050,81301356）
上海市自然科学基金(16ZR1426800) （16ZR1426800）
